Bioequivalence testing over new combination drugs to be made compulsory next July

Published: 2009-09-08 06:58:00

Updated: 2009-09-08 06:58:00

The Korea Food and Drug Administration announced that drug makers are required to conduct bioequivalence tests for new combination medicines from July next year as part of its efforts laid the foundation for Korean pharmaceutical companies to be able to comply with international GMP (good manufac...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK